ADC Therapeutics SA ROA 2019-2022 | ADCT

Current and historical return on assets (ROA) values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
ADC Therapeutics SA ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $-0.19B $0.52B -31.72%
2022-03-31 $-0.20B $0.58B -34.06%
2021-12-31 $-0.23B $0.62B -42.35%
2021-09-30 $-0.25B $0.64B -48.70%
2021-06-30 $-0.20B $0.46B -40.98%
2021-03-31 $-0.26B $0.46B -54.49%
2020-12-31 $-0.25B $0.51B -69.79%
2020-06-30 $-0.20B $0.37B -214.97%
2020-03-31 $-0.10B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00